NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash

Neurosense Therapeutics Ltd. ( (NRSN) ) just unveiled an announcement.

On December 30, 2025, NeuroSense Therapeutics held a Special Meeting of Shareholders at which investors approved three equity-related resolutions: grants of restricted shares to the company’s non-management directors for 2024, additional restricted shares to those directors in lieu of deferred cash fees to preserve financial flexibility, and a grant of restricted shares to Chief Executive Officer and director Alon Ben-Noon. The decisions, formally reported on January 6, 2026, underscore NeuroSense’s continued use of equity-based compensation to conserve cash resources and align the interests of its leadership and board with those of shareholders.

The most recent analyst rating on (NRSN) stock is a Hold with a $0.74 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

Spark’s Take on NRSN Stock

According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.

The score is driven primarily by weak financial performance (no revenue, widening losses, and substantial cash burn implying funding risk) and bearish technicals (below major moving averages with negative MACD). Valuation contributes limited support due to negative earnings and no dividend yield data.

To see Spark’s full report on NRSN stock, click here.

More about Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is an Israel-based biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company is listed in the United States as a foreign private issuer and reports under Form 20-F, targeting global capital markets to support its research and development activities.

Average Trading Volume: 314,786

Technical Sentiment Signal: Sell

Current Market Cap: $26.14M

For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.